Takeda Pharmaceutical (NYSE:TAK) Hits New 1-Year High at $16.34

Takeda Pharmaceutical Company Limited (NYSE:TAK – Get Rating)’s stock price hit a new 52-week high on Thursday . The company traded as high as $16.34 and last traded at $16.32, with a volume of 584870 shares. The stock had previously closed at $16.08.

Wall Street Analyst Weigh In

Separately, Bank of America raised shares of Takeda Pharmaceutical from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Thursday.

Takeda Pharmaceutical Stock Performance

The stock has a market cap of $51.87 billion, a price-to-earnings ratio of 24.83 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.75 and a current ratio of 1.16. The company’s 50 day simple moving average is $15.86 and its 200 day simple moving average is $14.59.

Takeda Pharmaceutical (NYSE:TAK – Get Rating) last released its earnings results on Thursday, February 2nd. The company reported $0.46 EPS for the quarter. The firm had revenue of $8.40 billion for the quarter. Takeda Pharmaceutical had a net margin of 6.84% and a return on equity of 12.43%. On average, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 2.16 earnings per share for the current year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Several large investors have recently bought and sold shares of the stock. Mondrian Investment Partners LTD increased its stake in Takeda Pharmaceutical by 10.0% during the 2nd quarter. Mondrian Investment Partners LTD now owns 4,751,715 shares of the company’s stock valued at $66,524,000 after buying an additional 432,000 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Takeda Pharmaceutical by 0.6% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 4,365,500 shares of the company’s stock valued at $68,102,000 after purchasing an additional 25,000 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Takeda Pharmaceutical by 13.7% in the first quarter. Goldman Sachs Group Inc. now owns 4,242,689 shares of the company’s stock worth $60,755,000 after buying an additional 509,886 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Takeda Pharmaceutical by 171.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,904,296 shares of the company’s stock worth $60,907,000 after buying an additional 2,465,178 shares during the period. Finally, BlackRock Inc. boosted its holdings in shares of Takeda Pharmaceutical by 38.6% in the first quarter. BlackRock Inc. now owns 3,021,274 shares of the company’s stock worth $43,265,000 after buying an additional 842,139 shares during the period. Institutional investors and hedge funds own 2.05% of the company’s stock.

About Takeda Pharmaceutical

(Get Rating)

Takeda Pharmaceutical Co, Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products.